GGrantIndex
← Leaderboards

David Evan Leaf

Brigham And Women'S Hospital

$10,646,805
Attributed
$11,933,865
Total exposure
6
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.6M · FY201325
$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,933,865 · 6

By mechanism

R01$8,611,693 · 3
U01$2,233,900 · 1
K23$964,140 · 1
F32$124,132 · 1

Top collaborators

Most similar at Brigham And Women'S Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Attenuated

Research focus

AttenuatedPlasmaAcute Renal Failure With Renal Papillary NecrosisCritical IllnessPreventAnimal ModelEnrollmentPlaySamplingPlacebosRandomizedKidneyInflammationInterleukin-6ComplexAcuteMonocyteInjuryHospitalsPostoperative PeriodHigh RiskIncidenceInnovationInjury Prevention

Grant awards (23)

Development, Validation, and Harmonization of Methods for Collection and Measurement of NAD+ and Related Metabolites: Application to a Randomized Trial of Patients Undergoing Coronary Artery Bypass$1,213,239
U01 · FY2025 · AG
Hepcidin-Ferroportin-Iron Axis in Cardiac Surgery-associated Acute Kidney Injury$767,918
R01 · FY2025 · DK · contact PI
Development, Validation, and Harmonization of Methods for Collection and Measurement of NAD+ and Related Metabolites: Application to a Randomized Trial of Patients Undergoing Coronary Artery Bypass$1,020,661
U01 · FY2024 · AG
Hepcidin-Ferroportin-Iron Axis in Cardiac Surgery-associated Acute Kidney Injury$733,320
R01 · FY2024 · DK · contact PI
Deferoxamine for the Prevention of Acute Kidney Injury$712,540
R01 · FY2024 · DK · contact PI
Hepcidin-Ferroportin-Iron Axis in Cardiac Surgery-associated Acute Kidney Injury$165,104
R01 · FY2024 · DK · contact PI
Hepcidin-Ferroportin-Iron Axis in Cardiac Surgery-associated Acute Kidney Injury$769,884
R01 · FY2023 · DK · contact PI
Deferoxamine for the Prevention of Acute Kidney Injury$734,798
R01 · FY2023 · DK · contact PI
Hepcidin-Ferroportin-Iron Axis in Cardiac Surgery-associated Acute Kidney Injury$815,283
R01 · FY2022 · DK · contact PI
Deferoxamine for the Prevention of Acute Kidney Injury$704,628
R01 · FY2022 · DK · contact PI
Precision Medicine Approach to Vitamin D3 Administration in Critical Illness$443,359
R01 · FY2022 · HL · contact PI
Deferoxamine for the Prevention of Acute Kidney Injury$654,578
R01 · FY2021 · DK · contact PI
Precision Medicine Approach to Vitamin D3 Administration in Critical Illness$443,876
R01 · FY2021 · HL · contact PI
Deferoxamine for the Prevention of Acute Kidney Injury$740,876
R01 · FY2020 · DK · contact PI
Precision Medicine Approach to Vitamin D3 Administration in Critical Illness$457,978
R01 · FY2020 · HL · contact PI
Precision Medicine Approach to Vitamin D3 Administration in Critical Illness$467,551
R01 · FY2019 · HL · contact PI
Dysregulated Mineral Metabolism and Acute Kidney Injury$197,640
K23 · FY2019 · DK · contact PI
Dysregulated Mineral Metabolism and Acute Kidney Injury$197,640
K23 · FY2018 · DK · contact PI
Dysregulated Mineral Metabolism and Acute Kidney Injury$197,640
K23 · FY2017 · DK · contact PI
Dysregulated Mineral Metabolism and Acute Kidney Injury$184,980
K23 · FY2016 · DK · contact PI
Dysregulated Mineral Metabolism and Acute Kidney Injury$186,240
K23 · FY2015 · DK · contact PI
Dysregulated Mineral Metabolism in Acute Kidney Injury$63,698
F32 · FY2014 · DK · contact PI
Dysregulated Mineral Metabolism in Acute Kidney Injury$60,434
F32 · FY2013 · DK · contact PI